Search

Your search keyword '"Delfraissy, Jean Francois"' showing total 21 results
Start Over Author "Delfraissy, Jean Francois" Topic aids
21 results on '"Delfraissy, Jean Francois"'

5. Causes and Determinants of Mortality in HIV-Infected Adults With Tuberculosis: An Analysis From the CAMELIA ANRS 1295-CIPRA KH001 Randomized Trial

Author

CAMELIA (ANRS 1295-CIPRA KH001) Study Team, Marcy, Olivier, Laureillard, Didier, Madec, Yoann, Chan, Sarin, Mayaud, Charles, Borand, Laurence, Prak, Narom, Kim, Chindamony, Lak, Kim Khemarin, Hak, Chanroeurn, Dim, Bunnet, Sok, Thim, Delfraissy, Jean-François, Goldfeld, Anne E., and Blanc, François-Xavier

Published
2014
Full Text
View/download PDF

7. Multicohort Genomewide Association Study Reveals a New Signal of Protection Against HIV-1 Acquisition

Author

Limou, Sophie, Delaneau, Olivier, van Manen, Daniëlle, An, Ping, Sezgin, Efe, Le Clerc, Sigrid, Coulonges, Cédric, Troyer, Jennifer L., Veldink, Jan H., van den Berg, Leonard H., Spadoni, Jean-Louis, Taing, Lieng, Labib, Taoufik, Montes, Matthieu, Delfraissy, Jean-François, Schachter, François, O'Brien, Stephen J., Buchbinder, Susan, van Natta, Mark L., Jabs, Douglas A., Froguel, Philippe, Schuitemaker, Hanneke, Winkler, Cheryl A., and Zagury, Jean-François

Published
2012
Full Text
View/download PDF

8. Multiple-Cohort Genetic Association Study Reveals CXCR6 as a New Chemokine Receptor Involved in Long-Term Nonprogression to AIDS

Author

Limou, Sophie, Coulonges, Cédric, Herbeck, Joshua T., van Manen, Daniëlle, An, Ping, Le Clerc, Sigrid, Delaneau, Olivier, Diop, Gora, Taing, Lieng, Montes, Matthieu, Wout, Angélique B. van't, Gottlieb, Geoffrey S., Therwath, Amu, Rouzioux, Christine, Delfraissy, Jean-François, Lelièvre, Jean-Daniel, Lévy, Yves, Hercberg, Serge, Dina, Christian, Phair, John, Donfield, Sharyne, Goedert, James J., Buchbinder, Susan, Estaquier, Jérôme, Schächter, François, Gut, Ivo, Froguel, Philippe, Mullins, James I., Schuitemaker, Hanneke, Winkler, Cheryl, and Zagury, Jean-François

Published
2010

10. Genomewide Association Study of a Rapid Progression Cohort Identifies New Susceptibility Alleles for AIDS (ANRS Genomewide Association Study 03)

Author

ANRS Genomic Group, Le Clerc, Sigrid, Limou, Sophie, Coulonges, Cédric, Carpentier, Wassila, Dina, Christian, Taing, Lieng, Delaneau, Olivier, Labib, Taoufik, Sladek, Rob, Deveau, Christiane, Guillemain, Hélène, Ratsimandresy, Rojo, Montes, Matthieu, Spadoni, Jean-Louis, Therwath, Amy, Schächter, François, Matsuda, Fumihiko, Gut, Ivo, Lelièvre, Jean-Daniel, Lévy, Yves, Froguel, Philippe, Delfraissy, Jean-François, Hercberg, Serge, and Zagury, Jean-François

Published
2009

12. Genomewide Association Study of an AIDS-Nonprogression Cohort Emphasizes the Role Played by HLA Genes (ANRS Genomewide Association Study 02)

Author

ANRS Genomic Group, Limou, Sophie, Le Clerc, Sigrid, Coulonges, Cédric, Carpentier, Wassila, Dina, Christian, Delaneau, Olivier, Labib, Taoufik, Taing, Lieng, Sladek, Rob, Deveau, Christiane, Ratsimandresy, Rojo, Montes, Matthieu, Spadoni, Jean-Louis, Lelièvre, Jean-Daniel, Lévy, Yves, Therwath, Amu, Schächter, François, Matsuda, Fumihiko, Gut, Ivo, Froguel, Philippe, Delfraissy, Jean-François, Hercberg, Serge, and Zagury, Jean-François

Published
2009
Full Text
View/download PDF

16. Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316

Author

Pediatric AIDS Clinical Trials Group Protocol 316 Team, Cunningham, Coleen K., Chaix, Marie-Laure, Rekacewicz, Claire, Britto, Paula, Rouzioux, Christine, Gelber, Richard D., Dorenbaum, Alejandro, Delfraissy, Jean Francois, Bazin, Brigitte, Mofenson, Lynne, and Sullivan, John L.

Published
2002

20. CCR5 DELTA32 Deletion and Reduced Risk of Toxoplasmosis in Persons Infected with Human...

Author

Meyer, Laurence, Magierowska, Magda, Hubert, Jean-Baptiste, Mayaux, Marie-Jeanne, Misrahi, Micheline, Le Chenadec, Jerome, Debre, Patrice, Rouzioux, Christine, Delfraissy, Jean-Francois, and Theodorou, Ioannis

Subjects
VIRAL receptors, AIDS, HIV-positive persons, TOXOPLASMOSIS
Abstract

Attempts to determine whether the viral receptor CCR5 delta32 deletion affected progression to certain first AIDS-defining illnesses in HIV-infected patients. Relative risk of toxoplasmosis associated with heterozygosity; Conditions progressive among the patients.

Published
1999

21. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease.

Author

Kotb, Rami, Vincent, Isabelle, Dulioust, Anne, Peretti, Delphine, Taburet, Anne-Marie, Delfraissy, Jean-Francois, and Goujard, Cécile

Subjects
ANTIVIRAL agents, HIV-positive persons, ANTINEOPLASTIC agents, HIV infections, COMMUNICABLE diseases, AIDS, THERAPEUTICS
Abstract

Background: HIV-infected patients still present a high risk of developing lymphoproliferative malignancies, despite the fact that their prognosis has been considerably improved by highly active antiretroviral therapy (HAART). Potential interactions exist between antiretroviral drugs, in particular protease inhibitors, and anti-neoplastic ones, but their impact in terms of clinical and haematological adverse events remains unclear. Methods: We report a case of potentially life-threatening interaction between vinblastine and antiretroviral therapy in a patient presenting with HIV-associated multicentric Castleman's disease (MCD). Results: A 55-year-old HIV-1 infected patient was diagnosed with MCD while being treated with a salvage HAART regimen consisting of zidovudine, lamivudine, abacavir, nevirapine and ritonavir-boosted lopinavir. Vinblastine was prescribed as a monotherapy at the usual dose of 6 mg/m2 (i.e. 10 mg) every 3 weeks. The first vinblastine course was performed without HAART with no adverse event. Antiretroviral therapy was resumed for the two following courses which were associated with unexpected severe digestive and haematological toxicities, and moderate renal failure. Vinblastine was then administered alone at increasing doses without toxicity. HAART was finally resumed and we assessed that a decreased vinblastine dose of 2 mg/m2 was well tolerated, with a complete response of MCD. Conclusions: HAART regimen comprising protease inhibitors, which are potent inhibitors of cytochrome P450 and P-gp, could interfere with anti-neoplastic drugs, as demonstrated with vinblastine in our case report. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results